A deep focus on molecular hallmarks has allowed us to identify and specifically distinguish a subset of advanced NSCLC patients harboring EGFR exon 20 insertions with the possibility of benefiting from targeted therapies, including bispecific antibodies such as amivantamab that demonstrate a high affinity and target both EGFR and MET [48]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.